GLP-1 lateral septum cravings are at the centre of a growing body of research suggesting that drugs such as Ozempic and Wegovy may do considerably more than suppress appetite: they appear to dampen the brain’s drive to seek out alcohol and other addictive substances, and scientists are beginning to identify the neural mechanism responsible.
Writing for The Conversation, Robert Munn, Senior Lecturer at the University of Otago, argues that the lateral septum, a brain region long associated with emotional regulation, is now emerging as a key control point between conscious craving and compulsive consumption. The region is, in his words, ‘absolutely loaded’ with receptors for the GLP-1 hormone that these drugs mimic.
GLP-1, the Lateral Septum, and Cravings: What the Research Shows
The conventional focus for reward research has been on the ventral tegmental area (VTA) and nucleus accumbens (NAc), the dopamine-producing regions of the brain. But Munn points out that these areas lack significant GLP-1 receptor density, making them unlikely candidates for the direct mechanism behind the anti-consumption effects observed in patients on GLP-1 agonists.
The lateral septum sits one step ‘upstream’ from those dopamine-producing regions. It receives substantial input from the hippocampus, the brain structure associated with long-term episodic memory, and recent research has shown it contains place cells that respond strongly to rewards. The picture that emerges is of a region that integrates ‘where and when am I’ information from the hippocampus with ‘what is good in this place’, then forwards that combined signal to the dopamine machinery. Neuroscientists now regard the lateral septum as the brain region that mediates conscious awareness of rewards before the dopamine response follows.
The historical footprint of the lateral septum is worth noting. In 1953, US behavioural researchers Joseph Brady and Walle Nauta coined the term ‘septal rage’ after observing that animals with damage in this region showed increased aggression, while direct stimulation reduced it. The region has since been reframed as a hub within a broader neural connectivity network, linked to the hypothalamus, hippocampus, and the reward circuitry further downstream.
GLP-1 activation directly in the lateral septum has been shown to reduce food consumption in mice. A separate study, published earlier this year, demonstrated the same effect for alcohol. Munn’s own laboratory has shown this year that GLP-1 drugs reduce a type of activity in the lateral septum that may prevent it from communicating effectively with other brain regions, which could help explain the observed reductions in craving-driven behaviour.
Clinical Evidence Across a Large Patient Base
The human evidence is still accumulating, but the scale is beginning to matter. A systematic review by Subhani et al. (2024), published in the International Journal of Molecular Sciences, synthesised clinical and observational data from six studies totalling over 88,000 participants, examining the effects of GLP-1 receptor agonists on alcohol use. The same review confirms that GLP-1 receptors are expressed not only in the lateral septum and hippocampus but also in the VTA, NAc, and the medial habenula, suggesting the drugs may act on the reward system through several routes simultaneously.
Preclinical animal studies cited by Munn suggest GLP-1 agonists also reduce the use of cocaine, amphetamines, opiates, and nicotine, though he is careful to distinguish those findings from the human evidence on alcohol, which is more directly established.
Beyond observational data, at least one trial has moved into randomised territory. A randomised clinical trial testing once-weekly semaglutide in adults with alcohol use disorder has been conducted and its results are available via Frontiers in Pharmacology. That represents a methodological step up from the observational studies that have dominated the literature so far, though the field will need further replication before any clinical consensus forms.
The broader question the research raises is whether the lateral septum, and the GLP-1 receptor system that modulates it, represents a genuine therapeutic target for addiction rather than an incidental finding attached to a weight-loss drug. The studies going back to the 1970s that linked vivid mental imagery with drug abuse suggested the craving-to-action pathway was a coherent mechanism; the lateral septum research now offers a candidate neural substrate for it.
The randomised semaglutide trial in alcohol use disorder patients is the kind of evidence the field has been waiting for, and its publication in a peer-reviewed pharmacology journal makes it the clearest clinical test of the hypothesis to date. Whether the results are sufficient to prompt regulatory or prescribing changes is a question for bodies beyond neuroscience, but the research trajectory now has both a plausible mechanism and a growing clinical dataset behind it.
